Adverse events recorded within day 0 to day 3 after MDA using dihydroartemisinin-piperaquine.</p
<p>Group A: 10-day esomeprazole/amoxicillin/levofloxacin triple therapy;</p><p>Group B: 14-day esome...
<p>*reported as possibly related.</p><p>Adverse events (AEs) during trial period (day 0–182) by vacc...
Uncommon and rare adverse events (AEs), with delayed onset may not be detected before new drugs are ...
Serious adverse events (MedDRA system organ classes) reported during follow-up.</p
<p>Adverse events: local and systemic adverse events 21 days after first dose and 42 days after the ...
Incidence of adverse events during on-treatment follow-up and whole study period.</p
The occurrence of adverse events after receiving the first and second dose in the participants with ...
The occurrence of adverse events after receiving the first and second dose in the participants with ...
<p>Treatment-emergent adverse events occurring during the Phase I study in at least two different su...
Related adverse events in treatment groups with or without IL-12 pDNA adjuvant.</p
<p>Treatment-emergent adverse events experienced by ≥5% of patients in either treatment group (treat...
<p>Treatment-emergent adverse events experienced by ≥3 patients in any treatment group in the Phase ...
<p>Serious adverse events in patients who completed all pharmacokinetic assessments (N = 25) and in ...
<p>Adverse drug reactions in MDR-TB/HIV co-infected patients under treatment.</p
Risk of adverse drug reactions by time period from the start of raltegravir treatment.</p
<p>Group A: 10-day esomeprazole/amoxicillin/levofloxacin triple therapy;</p><p>Group B: 14-day esome...
<p>*reported as possibly related.</p><p>Adverse events (AEs) during trial period (day 0–182) by vacc...
Uncommon and rare adverse events (AEs), with delayed onset may not be detected before new drugs are ...
Serious adverse events (MedDRA system organ classes) reported during follow-up.</p
<p>Adverse events: local and systemic adverse events 21 days after first dose and 42 days after the ...
Incidence of adverse events during on-treatment follow-up and whole study period.</p
The occurrence of adverse events after receiving the first and second dose in the participants with ...
The occurrence of adverse events after receiving the first and second dose in the participants with ...
<p>Treatment-emergent adverse events occurring during the Phase I study in at least two different su...
Related adverse events in treatment groups with or without IL-12 pDNA adjuvant.</p
<p>Treatment-emergent adverse events experienced by ≥5% of patients in either treatment group (treat...
<p>Treatment-emergent adverse events experienced by ≥3 patients in any treatment group in the Phase ...
<p>Serious adverse events in patients who completed all pharmacokinetic assessments (N = 25) and in ...
<p>Adverse drug reactions in MDR-TB/HIV co-infected patients under treatment.</p
Risk of adverse drug reactions by time period from the start of raltegravir treatment.</p
<p>Group A: 10-day esomeprazole/amoxicillin/levofloxacin triple therapy;</p><p>Group B: 14-day esome...
<p>*reported as possibly related.</p><p>Adverse events (AEs) during trial period (day 0–182) by vacc...
Uncommon and rare adverse events (AEs), with delayed onset may not be detected before new drugs are ...